Enanta Pharmaceuticals | ENTA - Trade Creditors


Enanta Pharmaceuticals reported $1.88M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
Anika Therapeutics USD 4.73M 39K Sep/2025
Arrowhead Research USD 32.94M 15.26M Dec/2025
AstraZeneca USD 25.28B 252M Dec/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
Biogen USD 432M 18.9M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Gilead Sciences USD 808M 226M Sep/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Halozyme Therapeutics USD 20.9M 5.54M Dec/2025
Heron Therapeutics USD 12.02M 20K Sep/2025
Immunic USD 7.92M 25K Sep/2025
Incyte USD 1.63B 1.46B Dec/2025
Insmed USD 79.91M 316K Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
J&J USD 11.99B 2.37B Dec/2025
Karyopharm Therapeutics USD 5.39M 2.8M Sep/2025
Ligand Pharmaceuticals USD 3.24M 24.52M Dec/2025
Merck USD 4.15B 102M Sep/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Novartis USD 4.56B 49M Sep/2025
Novavax USD 15.23M 35.37M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sarepta Therapeutics USD 280.84M 186.83M Dec/2025
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025